Development of a Mind Body Program for Obese Knee Osteoarthritis Patients with Comorbid Depression by Jacobs, Cale A. et al.
University of Kentucky 
UKnowledge 
Orthopaedic Surgery and Sports Medicine 
Faculty Publications Orthopaedic Surgery and Sports Medicine 
1-28-2021 
Development of a Mind Body Program for Obese Knee 
Osteoarthritis Patients with Comorbid Depression 
Cale A. Jacobs 
University of Kentucky, cale.jacobs@uky.edu 
Ryan A. Mace 
Massachusetts General Hospital 
Jonathan Greenberg 
Massachusetts General Hospital 
Paula J. Popok 
Massachusetts General Hospital 
Mira Reichman 
Massachusetts General Hospital 
See next page for additional authors 
Follow this and additional works at: https://uknowledge.uky.edu/orthopaedicsurgery_facpub 
 Part of the Orthopedics Commons, and the Psychiatry and Psychology Commons 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Repository Citation 
Jacobs, Cale A.; Mace, Ryan A.; Greenberg, Jonathan; Popok, Paula J.; Reichman, Mira; Lattermann, 
Christian; Burris, Jessica L.; Macklin, Eric A.; and Vranceanu, Ana-Maria, "Development of a Mind Body 
Program for Obese Knee Osteoarthritis Patients with Comorbid Depression" (2021). Orthopaedic Surgery 
and Sports Medicine Faculty Publications. 26. 
https://uknowledge.uky.edu/orthopaedicsurgery_facpub/26 
This Article is brought to you for free and open access by the Orthopaedic Surgery and Sports Medicine at 
UKnowledge. It has been accepted for inclusion in Orthopaedic Surgery and Sports Medicine Faculty Publications 
by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
Development of a Mind Body Program for Obese Knee Osteoarthritis Patients 
with Comorbid Depression 
Digital Object Identifier (DOI) 
https://doi.org/10.1016/j.conctc.2021.100720 
Notes/Citation Information 
Published in Contemporary Clinical Trials Communications, v. 21, 100720. 
© 2021 Published by Elsevier Inc. 
This is an open access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-
nc-nd/4.0/). 
Authors 
Cale A. Jacobs, Ryan A. Mace, Jonathan Greenberg, Paula J. Popok, Mira Reichman, Christian 
Lattermann, Jessica L. Burris, Eric A. Macklin, and Ana-Maria Vranceanu 
This article is available at UKnowledge: https://uknowledge.uky.edu/orthopaedicsurgery_facpub/26 
Contemporary Clinical Trials Communications 21 (2021) 100720
Available online 28 January 2021
2451-8654/© 2021 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Development of a mind body program for obese knee osteoarthritis patients 
with comorbid depression 
Cale A. Jacobs a,*, Ryan A. Mace b, Jonathan Greenberg b, Paula J. Popok b, Mira Reichman b, 
Christian Lattermann c, Jessica L. Burris d, Eric A. Macklin b, Ana-Maria Vranceanu b 
a Department of Orthopaedic Surgery & Sports Medicine, University of Kentucky, 740 S. Limestone, Suite K401, Lexington, 40536-0284, KY, USA 
b Integrated Brain Health Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, 1 Bowdoin Square, 1st Floor, Suite 100, Boston, 
02114, MA, USA 
c Department of Orthopedic Surgery, Brigham and Women’s Hospital, 850 Boylston Street, Chestnut Hill, 02467, MA, USA 
d Department of Psychology, University of Kentucky, 207K Kastle Hall, Lexington, 40506, KY, USA   








A B S T R A C T   
Knee osteoarthritis (OA) is the most common joint disorder in the U.S. and a leading cause of disability. 
Depression and obesity are highly comorbid among knee OA patients, and the combination of obesity and 
depression is associated with decreased physical activity, higher pain and disability, and more rapid cartilage 
degradation. Depression, obesity and OA exacerbate one another and share a common pathophysiology involving 
systemic inflammation and pro-inflammatory cytokines, reflecting a complex mind-body interaction. Current 
treatments for knee OA offer little to no benefit over placebo, and do not emphasize mind-body practices or 
physical activity to target the underlying pathophysiology. Mind-body interventions to lessen depressive 
symptoms and increase physical activity offer the ability to target biological, mechanical and psychological 
mechanisms of OA progression. Our long-term goals are to evaluate the mechanisms by which the Relaxation 
Response Resiliency Program (3RP) delivered via secure telehealth, and adapted for patients with depression, 
obesity and knee OA (GetActive-OA) promotes increases in physical activity and improved knee health. We 
hypothesize that the synergistic interaction between mindfulness, adaptive thinking, positive psychology and 
healthy living skills of the GetActive-OA will slow the progression of symptomatic knee OA by reducing pro- 
inflammatory cytokine expression and promoting optimal mechanical loading of the cartilage. Here we pre-
sent the protocol for a mixed methods study that will adapt the 3RP for the needs of knee OA patients with 
depression and obesity with a focus on increasing physical activity (GetActive-OA), and iteratively maximize the 
feasibility, credibility and acceptability of the programs and research procedures.   
1. Introduction 
Symptomatic knee osteoarthritis (OA) is the most common joint 
disorder in the United States and a leading cause of disability [1]. 
Depression and obesity are highly comorbid among knee OA patients [2, 
3] and this combination is associated with decreased physical function 
[4,5], higher pain and disability, and more rapid cartilage degradation 
[6]. Depression, obesity and OA exacerbate one another and share a 
common pathophysiology [7–9] that involves a cycle of increased 
proinflammatory cytokine interleukin 1-beta (IL-1β) and 
Toll-like-receptor 4 (TLR4) [10–12] activity which, in turn, leads to 
inflammation-induced cartilage catabolism in the knee. 
Current knee OA treatments offer little to no benefit over placebo, 
and do not emphasize mind-body practices linked with increased 
physical activity to target the underlying pathophysiology [13]. 
Increasing physical activity is particularly important as breaking the 
cycle of depression and inactivity associated with OA pain and cartilage 
degradation [5,14] can result in optimal loading of the articular carti-
lage. Light physical activities such as walking are associated with less 
knee pain [62] and may aid in preventing cartilage breakdown [63]. 
Walking is safe, commonly prescribed and preferred by patients. 
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However, sustained adherence is challenging due to multiple barriers 
including low mood, amotivation, weight, misconception about joint 
pain and stiffness, and inadequate problem solving and coping resources 
[15–20]. 
A mind-body intervention tailored to concomitantly address 
depression, obesity, and knee symptomatology integrated with quota 
based walking (e.g., gradual increase regardless of knee symptoms) has 
potential to increase knee function and slow OA progression through 
biological (e.g., reduced inflammation), mechanical (e.g., improved 
knee loading) and psychological (e.g., improved coping) mechanisms 
[21,22]. We previously adapted the Relaxation Response Resiliency 
Program (3RP) [17], a theory grounded, evidenced based mind-body 
program [18–23] for the unique needs of patients with chronic pain 
and to directly increase walking (GetActive program) [23,24] and 
showed high feasibility, acceptability, and satisfaction as well as a signal 
of improvement in pain, physical function, and emotional wellbeing. 
The GetActive program is amenable to further adaptations to directly 
address the interrelation of depression, obesity, knee dysfunction, as 
well as the older age of the typical knee OA patient, which present 
unique challenges to increased walking. 
Here we describe the study protocol for Project DOORSTEP which 
entails three phases: 1) adaptation of the GetActive program for live 
video delivery and the unique needs of patients with knee OA (GetAc-
tive-OA) with depression and obesity through expert multidisciplinary 
feedback and live video focus groups; 2) exploration of initial feasibility, 
credibility and acceptability of GetActive-OA, live video delivery and 
study procedures via an open pilot with exit interview; and 3) estab-
lishment of feasibility, credibility, acceptability and signal of improve-
ment in all facets of physical function (accelerometer step count, 40 m 
Fast-Paced Walk Test, self-report) [23,25–28] and biomarker outcomes 
of the refined GetActive-OA versus the Health Enhancement Program 
(HEP) [29], an educational time and dose matched control via a pilot 
RCT. A live video program is necessary in order to reach this patient 
population who lives far from orthopedic centers and prefers this de-
livery modality. Results will inform a fully powered RCT of 
GetActive-OA versus the control to test efficacy and mechanisms of 
improvement through biological and psychological pathways. 
2. Materials and methods 
2.1. Mixed-methods design 
Project DOORSTEP will use a mixed-methods approach to adapt, 
pilot and examine the credibility, acceptability, adherence and feasi-
bility of GetActive-OA delivered via secure live video (Fig. 1). Our three- 
phase approach is consistent with Obesity-Related Behavioral Inter-
vention Trials (ORBIT) [30] and National Center for Complementary 
and Integrative Health (NCCIH) models of intervention development, in 
which multiple program iterations are necessary to optimize feasibility 
and methodology before conducting larger efficacy clinical trials. Our 
team has applied these evidence-based frameworks and mixed-methods 
to adapt the 3RP for patients with heterogeneous chronic pain 
Abbreviations 
3RP Relaxation Response Resiliency Program 
ASES Arthritis Self Efficacy Scale 
BMI Body mass index 
CSQ Client Satisfaction Questionnaire 
CTX-Iα α isomerized version of the C-terminal crosslinked 
telopeptide of type I collagen 
CTX-II C-terminal crosslinked telopeptide type II collagen 
ELISA Enzyme-Linked Immunosorbent Assay 
HEP Health Enhancement Program 
IL-1β Interleukin 1-beta 
IMMPACT Initiative on Methods, Measurement, and Pain 
Assessment in Clinical Trials 
IRB Institutional Review Board 
KOOS Knee injury and Osteoarthritis Outcome Scale 
MGH Massachusetts General Hospital 
MOCS Measures of Current Status 
MPGI Modified Patient Global Impression of Change 
MRI Magnetic Resonance Imaging 
NCCIH National Center for Complementary and Integrative Health 
NRS Numerical Rating Scale 
OA Osteoarthritis 
OARSI Osteoarthritis Research Society International 
OMERACT Outcome Measures in Rheumatology 
ORBIT Obesity-Related Behavioral Intervention Trials 
PCS Pain Catastrophizing Scale 
PHQ-9 Patient Health Questionnaire-9 
RCT Randomized Controlled Trial 
RR Relaxation Response 
SMART Specific, Measurable, Achievable, Relevant, and Time 
bound 
TLR4 Toll-like-receptor 4 
UK University of Kentucky  
Fig. 1. Phases of Project DOORSTEP and development of the GetActive-OA program.  
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(GetActive program) [23,24] and neurofibromatosis and stroke [31,32]. 
The Institutional Review Boards (IRBs) at the University of Kentucky 
and Massachusetts General Hospital have approved all study procedures 
(IRB #53457). The research team and an external data safety and 
monitoring committee will provide ongoing oversight of project 
DOORSTEP. 
2.2. Participants and recruitment 
The same recruitment procedures and eligibility criteria will be used 
for all three phases of this project. Eight patients will be recruited to 
participate in the focus group interviews, eight patients will be enrolled 
in the open pilot study and complete exit interviews in Phase 2 (feasi-
bility pilot), and 60 different patients will be enrolled in Phase 3 
(feasibility RCT; up to 4 group cohorts of GetActive-OA each with 6–8 
participants vs. up to 4 groups cohorts of HEP each with up to 8 par-
ticipants). Eligible patients with mild to moderate knee OA, using 
standard diagnostic criteria, will be referred by seven physicians at the 
University of Kentucky (UK) Healthcare Hip & Knee Center and the UK 
Healthcare Orthopedic & Sports Medicine Center during regularly 
scheduled office visits. Standard diagnostic criteria will include clinical 
examination, patient-reported symptoms/functional limitations, and 
radiographic assessments. In addition, because the focus group activities 
can all be completed remotely, the IRB-approved study flyer will be 
circulated electronically at the participating institutions. 
Inclusion criteria are: obesity (BMI ≥ 30 kg/m2), idiopathic knee OA 
[33] with mild to moderate radiographic changes (Kellgren/Lawrence 
grade 2 or 334 or Knee injury and Osteoarthritis Outcome Scores (KOOS) 
consistent with knee OA [35]), elevated depressive symptoms (PHQ-9 ≥
103,[36,37]), age 45 or older [38,39], history of concurrent psychotro-
pics for < 2 weeks prior to initiation of treatment or on stable doses for 
> 6 weeks, access to an internet-enabled computer/smart phone, will-
ingness to comply with the study protocol and assessments, and cleared 
by a medical doctor to participate. Exclusion criteria are: any disorder 
requiring the use of systemic corticosteroids; rheumatoid arthritis; his-
tory of cancer within 5 years of screening; unable to 
walk/wheelchair-bound; prior surgical fixation of a femur or tibia 
fracture; taking high doses of opioid pain medication (>50 mg of 
morphine equivalent per day); diagnosis of a medical illness expected to 
worsen in the next 6 months (e.g., malignancy); active suicidal ideation 
or past-year psychiatric hospitalization; non-English speaking; lifetime 
history of schizophrenia, bipolar disorder, or other psychotic disorder; 
current substance abuse or dependence (or a history within the past 6 
months); practice of yoga/meditation, or other mind body techniques 
once per week > 45 min within the last 3 months; engagement in regular 
moderate or vigorous physical exercise for >30 min daily. These criteria 
are consistent with other clinical trials in knee OA or mind-body in-
terventions [31,39]. Patients with reduced or altered capacity due to 
administration of any mind-altering substances such as tranquilizers, 
conscious sedation or anesthesia, brain injury, or age outside of the 
targeted range will not be recruited for participation in this study. 
Enrollment and baseline data collection (self-report questionnaires, 
blood draws, urine samples) will coincide with the patient’s office visit 
with their treating physician and will not require an additional visit. 
After providing verbal consent, potential participants will meet with a 
research assistant for study screening. If the screening indicates that the 
patient meets all inclusion and exclusion criteria, study staff will begin 
the written informed consent process. 
Eligible participants will undergo written informed consent prior to 
the focus group interview (Phase 1) or baseline assessments (Phases 
2–3). Due to the sensitive data collected in this study, patients will re-
view and sign the combined informed consent and HIPAA-authorization 
if they choose to participate. The informed consent process will take 
place in a dedicated research room at either facility to ensure that both 
the patient and research team have adequate time and privacy. A spe-
cific item will be included on the Informed Consent and Data Collection 
Checklist Forms to ensure that “Patients were asked if they had any 
questions (Yes/No).” The patient will then be given the option to pro-
vide informed consent that day, to return on a different day, or opt out. 
Study staff will coordinate scheduling to continue the informed consent 
process with patients as needed. A copy of the completed informed 
consent will be given to patients, added to their medical records, and 
documented in study progress notes. 
2.3. Live video delivery 
Participants will be recruited in-person at the University of Ken-
tucky, but will also be recruited via electronic means at the other study 
sites (Massachusetts General Hospital (MGH) and Brigham & Women’s 
Hospital (BWH)). The focus groups and intervention will be performed 
remotely by the study team at MGH. All three phases will be conducted 
via live video through a HIPPA-approved software used in clinical 
practice at MGH for a variety of medical populations. We have extensive 
experience with delivery of similar mind-body programs and focus 
groups via live video.102,121 We plan to start with this prior methodology 
and modify it as needed based on information from the focus group. 
After enrollment, participants will receive an emailed link for one-click 
installation of the video software. A research assistant will offer par-
ticipants a test call and assist with installation as needed. Participants 
will receive a reminder email about the appointment information and a 
link to access the virtual group session. The research assistant will be 
available to assist participants in real time with any technical challenges 
they may experience during the focus groups (Phase 1) and treatment 
sessions (Phases 2 and 3). 
2.4. Phase 1: development of the GetActive-OA program 
The goal for Phase 1 of project DOORSTEP is to develop the 
GetActive-OA program. First, we will use existing literature and multi-
disciplinary expertise to propose modifications to the original GetActive 
program. Next, we will develop a semi-structured qualitative interview 
guide to conduct live video focus groups to gather feedback from the 
target population on the GetActive-OA and Project DOORSTEP pro-
cedures. All proposed changes will be finalized after these interviews, 
and other revisions will likely occur after the open pilot and exit 
interviews. 
2.4.1. Conceptual model for GetActive-OA 
Fig. 2 presents the conceptual model of GetActive-OA that will guide 
adaptations for the GetActive program. We hypothesize that participa-
tion in the GetActive-OA will be associated with decreased pro- 
inflammatory IL-1β and TLR4 expression, increased resiliency skills (e. 
g., increased mindfulness and OA self-efficacy, and decreased pain cat-
astrophizing) and increased physical function (measured through self- 
report, walk test, and accelerometer). In turn, these factors will be 
associated with decreased depression and obesity, leading to better knee 
health (i.e., decreased cartilage biomarkers, decreased pain/stiffness, 
and increased function). The GetActive-OA will thus directly target the 3 
causal pathways associated with rapid knee degradation: biological, 
mechanical and psychological. Although not depicted in this figure, 
several relationships are bidirectional, including those between 
inflammation and depression, inflammation and obesity, and physical 
function and depression [40–44]. 
2.4.2. Program structure and modification 
The GetActive-OA program will retain core components of the 
GetActive program, including (1) mind-body skills to elicit relaxation (e. 
g. deep breathing, mindfulness meditation): and minimize negative 
reactivity to pain and reduce activity avoidance; (2) cognitive behav-
ioral skills that are pain-specific (e.g., behavioral activation techniques, 
goal-setting, adaptive restructuring of negative reactions to pain such as 
catastrophizing and fear avoidance) to remove barriers to getting active, 
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and (3) skills for physical restoration (e.g., quota-based pacing non- 
contingent on pain) to systematically increase walking. We will adapt 
these skills to meet the specific needs, preferences, and challenges of 
patients with knee OA and comorbid depression and obesity (Table 1). 
We will also add several novel components to the GetActive-OA 
program. First, we will provide educational information on the bio-
psychosocial interactions among knee OA, depression, and obesity that 
comprise a population-specific disability spiral. Inflammation is the 
biological tie among the 3 conditions and physical activity is a modifi-
able factor that can decrease inflammation, improve the biology and 
function of the knee, and decrease both depression and obesity [7–9, 
45–52]. This will be used to provide a rationale for learning skills to 
directly address the 3 comorbidities, all of which are known barriers to 
increasing physical function and walking. 
Second, we will directly address obesity by making novel modifica-
tions to the healthy eating educational information in the original 3RP. 
Participants will be taught to apply mindfulness skills to eating (mindful 
eating, noticing automatic urges) using behavioral economics principles 
(e.g., food shopping and placement), and engaging the entire family 
structure to make changes in diet and exercise. 
Third, we will strive to reduce stigma faced by patients with these 
comorbidities. Our multidisciplinary team will revise the treatment 
manual for patient-sensitive language. Patients will learn to practice 
self-compassion to reduce self-criticism common in patients with 
depression and obesity, to prevent discouragement and dialectics (e.g., 
acceptance versus change) and to address ambivalence with making 
lifestyle changes. 
Fourth, when discussing and targeting coping with the physical 
sensations associated with knee OA, rather than focusing exclusively on 
pain, we will specifically address other types of physical discomfort 
common in patients with knee OA, including stiffness, swelling, pres-
sure, and limited range of movement. These post-activity sensations are 
often misinterpreted as damage and can further contribute to fear of 
pain, activity avoidance, and associated walking challenges that fuel the 
disability spiral [40–47]. We will reinforce that walking is safe [53], and 
associated with knee health. 
Finally, although the 3RP, from which we developed the GetActive 
program, has been adapted for live video in patients with neurofibro-
matosis [31,32,54,55], we will optimize our live video procedures for 
this OA population. We are delivering the intervention to patients in 
rural areas who may have lower health literacy, which we have not done 
before. We will revise the manual with special attention to simplifying 
the language and eliminate less relevant skills from the GetActive pro-
gram to reduce burden and allow more time for learning. We will 
consider developing specific practice aids (e.g., reminder calls or text, 
caregiver involvement). Patients with knee OA are able to successfully 
use technology (e.g., accelerometers, live video) if they perceive it as 
easy [56]. To this end, they will receive daily reminders to complete 
their home practice log on their smartphone [41]. 
We anticipate that the GetActive-OA will have eight 90-min sessions 
equally spaced over the course of 8 weeks; however, the exact structure 
will depend on the results of the focus groups. Participants will be 
assigned homework between sessions, which includes developing 
mindfulness and other meditation-based practices, writing down 3 ap-
preciations, and setting a weekly SMART goal. SMART is an acronym to 
guide goal setting, standing for Specific, Measurable, Achievable, 
Fig. 2. Conceptual model of GetActive-OA for obese knee osteoarthritis patients with comorbid depression targeting the 3 pathways of rapid knee degradation 
(biological, mechanical and psychological). 
Table 1 
Proposed modifications of GetActive-OA.  
Session GetActive Skills GetActive-OA Proposed 
Modifications 
1 Pain myths, body awareness, pain 
disability spiral, setting activity 
SMART goals, quota-based 
activity pacing, gratitude 
Myths about knee OA; disability 
spiral of knee OA, obesity and 
depression; setting activity SMART 
goals; quota-based activity pacing; 
gratitude 
2 Activity barriers, pairing steps 
with activities of daily living, 
relaxation vs. stress response, 
deep breathing, single-pointed 
meditation, body scan, sleep 
hygiene 
Self-compassion with body image; 
depression and setbacks with goals; 
walking barriers; relationship 
between mood, pain, and activity; 
pairing walking with activities of 
daily living; deep breathing; single- 
pointed meditation; body scan; 
sleep hygiene 
3 Mindful awareness, mindfulness 
of pain, stress warning signals, 
social support, the pain cycle, 
walking meditation 
Mindfulness for knee OA, 
depression, and hunger ques; 
mindfulness of knee pain or 
discomfort; social support and 
coping with the stigma of pain, 
depression and obesity; effective 
communication; walking 
meditation 
4 Movement to illicit the relaxation 
response, pairing activity with 
mind-body skills, negative 
automatic thoughts and adaptive 
thinking 
Yoga for knee health; mindfulness 
of pain and discomfort; mindful 
walking; noticing the benefits of 
walking; negative automatic 
thoughts and common “thinking 
traps” in knee OA, depression and 
obesity; adaptive thinking; 
acceptance-based skills 
5 Guided imagery, adaptive 
thinking, healthy eating, “Stop, 
Breathe, Reflect, Choose” for 
stress and pain 
Healthy active self (guided imagery 
on visualizing a happy active life 
and a healthy knee); Mindful 
eating; “Stop, Breath, Reflect, 
Choose” adapted for eating choices, 
coping with pain and depression 
6 Loving kindness meditation, 
cultivating optimism, relaxation 
signals, “Getting Back on Track” 
after a lapse in activity 
Loving kindness meditation 
(emphasis on depression and 
obesity-related self-criticism), 
cultivating optimism, “Getting Back 
on Track” after a lapse in activity 
7 Problem solving and acceptance, 
empathy and compassion, 
contemplation-based meditation 
for pain management and activity 
Acceptance versus change dialectic 
in pain and OA, meditation on 
acceptance versus change 
8 Humor and laughter, “Idealized 
Self” for continued skills use after 
the program, staying resilient for 
pain management, overview of 
resiliency skills 
Humor and laughter, “Idealized 
Self” for continued skills use after 
the program, staying resilient for 
pain management, overview of 
resiliency skills  
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Relevant, and Time bound. 
2.4.3. Focus groups 
We will identify the treatment needs and preferences of patients with 
comorbid knee OA, depression and obesity via 2 focus groups (N = up to 
8 per group; 90 min). We will conduct the focus groups via live video to 
simulate participants in the intervention and elicit patient feedback on 
this delivery modality. The focus group interviews will be audio recor-
ded and transcribed to further improve the GetActive-OA, tailor its live 
video delivery, and inform data collection procedures including blood 
and urine biomarkers. We will develop a semi-structured qualitative 
interview guide to gather feedback on: (1) challenges of living with 
comorbid knee OA, depression, and obesity; (2) patients’ experiences 
with medical and complementary treatments; (3) knowledge about ex-
ercise recommendations for knee OA and interest in increasing walking; 
(4) perceptions of the GetActive-OA interventions; and (5) barriers to 
live video-delivery of the GetActive-OA, program adherence (group 
participation, homework completion), and data collection. 
2.4.4. Phase 1 deliverables 
After completing the focus group interviews, we will (1) refine the 
GetActive-OA manual to meet population-specific needs; (2) problem- 
solve potential barriers to adherence to in-session participation, home-
work and assessments (accelerometer, blood collection, self-reports); (3) 
solidify inclusionary and exclusionary criteria; and (4) finalize in-
struments to use in Phase 2. 
2.5. Phase 2: open pilot and exit interviews 
In Phase 2 of project DOORSTEP, we will conduct an open pilot of the 
newly developed GetActive-OA with individual exit interviews to 
explore preliminary credibility, acceptability, satisfaction with treat-
ment, feasibility of recruitment, instruments, biological data collection, 
and adherence to homework and walking recommendations. 
2.5.1. Open pilot 
Procedure. The study clinician, a clinical psychologist with experi-
ence in mind-body interventions for heterogeneous pain conditions, will 
deliver one open pilot group (N = 8) of GetActive-OA via the secure 
video platform used for the focus groups. The first session of GetActive- 
OA orients participants to program expectations, which includes eight 
weekly live video group sessions (90 min each) and assigned home 
practice. Each week, the study clinician will introduce new GetActive- 
OA skills, guide participants in setting a walking SMART goal, assign 
home practice (walking, mind-body exercises, gratitude, and pain logs), 
and problem-solve adherence issues that emerge. Participants who 
achieved their walking goal from the previous week will be encouraged 
to increase their goal by 10–20% according to guidelines for quota- 
based pacing [57]. Participants who do not meet their step goal will 
be asked to reattempt (unsuccessful for one week) or lower (unsuccessful 
for two consecutive weeks) their step goal with the guidance of the study 
clinician. The research coordinators will troubleshoot technical diffi-
culties with the live video platform and smartphone completion of the 
homework log. Participants that miss a group session will be contacted 
immediately by study staff and scheduled for a make-up of the 
GetActive-OA material. 
The treatment fidelity process for the RCT will follow NIH recom-
mendations125 and our previously successful clinical adherence protocol 
[102]. The clinician will complete fidelity checklists after each session 
and will undergo weekly supervision to reinforce protocol adherence. 
All sessions will be audio-recorded, and a random sample (10%) will be 
coded by an independent coder to evaluate protocol fidelity for both the 
intervention and control. Depression severity and suicidality will be 
monitored within study procedures and reviewed weekly using our 
3RP-specific live video risk assessment protocol [55]. Participants will 
be asked to provide information for 2 emergency contacts. All patients 
will be informed that in the case of worsening of depression or suici-
dality by self-report, a warm hand-off will be done to connect the patient 
with a local clinical psychologist for a safety assessment. Participant 
referrals for appropriate levels of care will be completed as needed. 
Assessments. The self-report measures and assessment domains were 
selected consistent with Initiative on Methods, Measurement, and Pain 
Assessment in Clinical Trials (IMMPACT), Osteoarthritis Research So-
ciety International (OARSI), and Outcome Measures in Rheumatology 
(OMERACT) recommendations [27,28], purpose of study [28], and 
recommendations for feasibility trials (Table 2) [30,58]. Before and after 
the GetActive-OA program, participants will be asked to travel to the 
local study site to receive their accelerometer and collect biological data. 
Accelerometer data. ActiGraph wGT3X-BT accelerometers (Acti-
Graph, LLC, Fort Walton Beach, FL, USA) will objectively assess physical 
activity the week before and after the GetActive-OA intervention. This 
accelerometer is widely used to ecologically assess physical functioning 
outcomes in chronic pain and older adult trials [24,59–61]. Participants 
will be instructed to wear the accelerometer on a belt located at their 
natural waistline with the unit located on either their right or left hip in 
line with the axilla. Participants will be asked to wear the accelerometer 
from the time they awake until the time they retire (at least 10 h) except 
when in contact with water [60]. To optimize ActiGraph adherence, 
each participant will: (1) receive ActiGraph wear instructions (device 
placement, troubleshooting, when to remove it); (2) create an individ-
ualized wear plan with the study staff; (3) complete a daily standardized 
wear time log (time worn/off, physical activities); and (4) select 
preferred method of contact for daily reminders via phone, email, or 
texts. To reduce the observer effect, all participants will be instructed to 
maintain their current level of physical activity to the best of their 
ability. Participants will mail the accelerometers using prepaid enve-
lopes after one week [62]. This procedure has led to high adherence in 
our prior research [23]. 
Biomarker data. Biomarkers analyses will utilize serum and urinary 
markers to avoid challenges associated with collection of knee synovial 
fluid [6]. The selected biomarkers have been shown to be predictive of 
inferior clinical outcomes and cartilage thinning [63,64], and are 
responsive to change over 3-month follow-up [65–67]. These validated 
biomarkers allow accurate assessment of short-term cartilage degrada-
tion and bone remodeling without the high cost or patient burden 
associated with imaging techniques such as magnetic resonance imaging 
(MRI). 
CTXII and CTXIα will assess cartilage breakdown and bony remod-
eling, respectively. Following cartilage degradation, CTXII (C-terminal 
crosslinked telopeptide type II collagen) is released into the synovial 
fluid and the circulation. CTXII will be measured in the urine by ELISA 
(Cartilaps® (CTX-II); Immunodiagnostic Systems, Inc, Fountain Hills, 
AZ) [65,66], and will be normalized to creatinine levels (Quidel, San 
Diego, CA) [64,68]. CTXIα (an alpha isomerized version of the C-ter-
minal crosslinked telopeptide of type I collagen) is localized to areas of 
high turnover of subchondral bone [68], and has been found to be 
predictive of OA symptom and radiographic progression [64]. CTXIα 
will be measured in the urine by sandwich ELISA (Nordic Biosciences, 
Herlev, Denmark), and like CTXII, will be normalized to urinary creat-
inine levels [64,68]. 
OA biomarker data collected will be carefully analyzed with respect 
to variability, linear range of standard, and need for repeat analyses. 
Controls provided with commercially available ELISA kits will be used 
with every run. For assays for which no control is available or provided, 
aliquots of serum from normal human subjects have been aliquoted and 
frozen at − 80 ◦C for this purpose. Each assay day, a fresh aliquot of this 
control serum is thawed and used on every plate to calculate intra- and 
inter-assay variance of the assay. In addition to the standard curve run in 
duplicate, this control will be run with each assay and the results used to 
determine the precision of the assay and to establish an acceptable 
control range for the assay. The mean of the control sample for all assays 
±2 standard deviations is defined as the acceptable control range. Any 
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samples on a plate in which the control falls outside of this range will be 
excluded and repeated. Samples will be run in duplicate and reanalyzed 
if the coefficient of variation is >15%. For values that are below the level 
of detection, a value equivalent to 0.5 lowest limit of detection will be 
recorded and used for statistical analyses [6,65,66]. 
2.5.2. Exit interviews 
After the open pilot, we will audio record and transcribe in-person 
exit interviews conducted by the psychologist with each patient (30 
min each). Exit interviews will assess: (1) the rationale and helpfulness 
of each GetActive-OA component for targeting knee OA, depression, and 
obesity; (2) perceived increase in physical function and usefulness of 
skills to increase walking; (3) experience with live video delivery 
(number and types of problems, satisfaction); (4) usefulness and 
adherence to home practice; and (5) burden and utility of assessments 
(biological samples, accelerometer compliance, self-reports) [23,32,86]. 
2.5.3. Phase 2 deliverables 
After completing the open pilot, we will further refine the GetActive- 
OA intervention, manual and study protocol prior to initiating Phase 3’s 
randomized controlled trial. We will also report markers of preliminary 
feasibility. 
2.6. Phase 3: pilot randomized controlled trial 
In Phase 3 of project DOORSTEP, we will conduct a pilot RCT of the 
GetActive-OA versus HEP. The goal of the pilot RCT is to assess the 
feasibility of recruitment procedures (e.g., screening, eligibility, 
enrollment rates), the feasibility and acceptability of the GetActive-OA 
and control interventions (e.g., adherence, retention, fidelity, satisfac-
tion, group live video delivery), and the feasibility of data collection 
procedures by group (e.g., adherence, satisfaction, accelerometer data, 
blood and urine biomarker data). In line with common guidelines for 
feasibility studies [47], we will not test efficacy or perform 
between-group analyses. 
We will enroll up to 60 patients and conduct up to 8 cohorts (4 
GetActive-OA and 4 HEP control with 7–8 participants per group). 
Participants will be randomized in a 1:1 design using a randomization 
scheme developed by the study statistician. The procedures from Phase 2 
will be repeated aside from strategies to optimize the protocol developed 
from the open pilot results. 
The control group will have the same format and procedures as the 
GetActive-OA and will follow the format of the HEP [32]. We will 
modify this program for the specific needs of patients with knee OA. 
Session structure is outlined in Table 3. To control for between-session 
practice, participants will receive an audio recording and informa-
tional handout to complete after each session. All of the patient educa-
tion information, in a simplified form, will be included in the 
GetActive-OA manual utilized by the research team. We have success-
fully used this procedure in our clinical trial in neurofibromatosis [32]. 
2.6.1. Phase 3 deliverables 
We will calculate descriptive statistics for biochemical biomarkers of 
Table 2 
Assessments tools.  
Construct Measurement tool and schedule 
Demographics Age, biological sex, body mass index (BMI), race/ 
ethnicity, educational level, employment status, 
occupation, income, marital status, mental health 
history, current psychotropic/pain medication 
intake, comorbid medical conditions, history of 
depression or other mental health conditions. Pre, 
Post. 
Pain  • Numerical Rating Scale (NRS) [69,70]; 11-point 
scale from 0 (no pain) to 10 (worst pain); Pre, 
Post.  
• Use of rescue analgesics. Daily self-report log.  
• Concomitant pain treatment. Daily self-report log. 
Pre, Post. 
Physical Function: Self- 
reported  
• Knee injury and Osteoarthritis Outcome Score 
(KOOS) [71,72]; assesses OA pain, symptoms, and 
knee-related quality of life, and one’s ability to 
carry out activities that require physical actions, 
ranging from self-care to social activities and work. 
Pre, Post. 
Physical Activity: Objective 
and self-report  
• Accelerometer [73,74]; measure activity during 7 
days both at baseline and post intervention. We 
will assess number of steps, as well as minutes of 
spent in light, moderate, and vigorous activity as 
well as minutes of sedentary time. Pre, Post.  
• Physical Activity Scale for persons with physical 
disability (PASPD); assesses leisure, household and 
work activities. Pre, Post. 
Physical Function: 
Performance-based  
• 40 m Self-Paced Walk Test [75,76]; assesses time 
necessary to walk 40 m. Pre, Post. 
Emotional Function  • PROMIS depression, v1.0.8b [77]; assesses 
negative mood, views of self and cognitions. Pre, 
Post.  
• PROMIS anxiety, v1.08a [78]; assesses fear, worry, 
hyperarousal and somatic symptoms, Pre, Post. 
Coping  • Pain Catastrophizing Scale (PCS) [79]; assesses 
hopelessness, helplessness and rumination about 
pain. Pre, Post.  
• Arthritis Self-Efficacy Scale (ASES); a valid 20-item 
instrument assessing self-efficacy in OA patients 
[80,81]. The ASES consists of 3 subscales (Pain, 
Function, and Other Symptoms) [80]. Pre, Post.  
• Measures of Current Status (MOCS) [82]; assesses 
ability to engage in a series of healthy coping skills 
(e.g., relaxation, social support, adaptive 
thinking). Pre, Post. 
Improvement (Patient’s 
Perspective)  
• Modified Patient Global Impression of Change 
(MPGI) [83]; 2 item assessing the extent to which 
patients perceive the intervention improved 
functioning and symptoms. Post. 
Credibility, Expectancy  • The Credibility and Expectancy questionnaire 
(CEQ) [84] assesses treatment expectancy and 
credibility in clinical outcome studies. Pre. 
Satisfaction  • Client Satisfaction Questionnaire (CSQ-3) [85]; 
assesses satisfaction with program on 3 
dimensions. Post. 
Adherence to 3RP 
homework and activity  
• SMART goals; RR practice; Appreciations; Activity 
log. Adverse events. Daily self-report log. 
Adherence to 
Accelerometer  
• Daily wear of Actigraph accelerometer for baseline 
and post intervention assessments. Pre, Post. 
Cartilage breakdown  • Urinary CTXII will be used to quantify cartilage 
degradation as this marker has been previously 
identified as being predictive of the progression of 
radiographic knee OA and knee OA symptoms [64, 
68]. Pre, Post. 
Bony remodeling  • Urinary CTXIα will be used to quantify OA-related 
bone turnover as this marker has been previously 
identified as being predictive of the progression of 
radiographic knee OA and knee OA symptoms 
[64]. Pre, Post. 
Systemic inflammation  • Proinflammatory cytokine IL-1β and Toll-like- 
receptor 4 (TLR4) will be assessed using ELISAs. 
Pre, Post.  
Table 3 
Structure of the Health Enhancement Program to be utilized with the control 
group.  
Session Health Enhancement Program Topics 
1 Educational information on depression, obesity and knee function 
including the role of inflammation 
2–3 Educational information on physical activity and effects on mood, weight 
and knee function 
4–5 Educational information on nutrition 
6 Educational information on sleep 
7 Educational information on navigating medical care 
8 Review  
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OA [6,66], depressive symptoms, body weight, physical function, and 
coping variables. We will also report definitive feasibility and accept-
ability markers for the GetActive-OA, the control intervention, and the 
study data collection and analysis procedures. This will provide a real-
istic assessment of the study procedures as they will occur during the 
fully-powered efficacy trial, information on how participants might 
engage differently with the intervention and control, and signal of 
improvement in the intervention before investment of resources in the 
full RCT. 
2.7. Analysis plan 
2.7.1. Qualitative data analyses (phases 1 and 2) 
The focus group and exit interviews will be audio recorded, tran-
scribed and iteratively analyzed using thematic content analyses 
following Miles and Huberman (1984) [87] in NVivo 11. The research 
assistant and clinician, who both have prior expertise in qualitative 
analyses, will conduct the analyses under the supervision of the research 
team’s senior psychologist. Each transcript will be separately reviewed 
to identify common patterns and themes and develop a coding frame-
work based on the interview scripts. Coding will be reviewed to ensure 
the reliability of the results. All discrepancies will be resolved through 
discussions with the research team’s senior psychologist and by 
comparing codes to the raw data until a high level of reliability is 
reached (Kappa>80) [23]. 
2.7.2. Quantitative data analyses (phases 2 and 3) 
Blinded quantitative analyses and randomization will be overseen by 
the research team’s statistician, who has extensive expertise in analyzing 
mind-body clinical trials across the stages of intervention development. 
We will report feasibility as number of participants approached, 
screened, eligible, and enrolled. We will report number of participants 
who completed at least 6 out of the 8 sessions (75%), along with the 95% 
confidence interval (CI) around this discontinuation rate. The research 
team’s senior clinical health psychologist will assess adherence to 
treatment by listening to the audio recorded sessions and analyzing the 
therapist adherence checklists. The research team’s senior psychologist 
will rate adherence for the 2 groups led by the study clinician in Phase 3. 
The research team’s senior orthopedic researcher will assess the number 
of days participants wore the accelerometers at baseline and post-test 
using the active wear time of 10 h/day [60]. The research team’s se-
nior orthopedic researcher will assess the number of missing specimens 
as well as the number of samples with values below the limits of 
detection. We will also report information on preliminary acceptability 
from quantitative and qualitative data, as well as information on cred-
ibility of intervention and adherence to GetActive-OA home practice. 
Consistent with guidelines for intervention development that 
emphasize a focus on feasibility prior to efficacy testing, feasibility 
markers were specified a priori.[21,29] Benchmarks provide clear 
guidelines for whether or not to move to an efficacy trial, or whether 
further modification of the intervention and study procedures are 
necessary prior to efficacy testing. The following benchmarks are 
required before undergoing the future fully powered RCT and have been 
used in our previous work:[23,34] 1) > 70% participants with Credi-
bility and Expectancy score [84] and Client Satisfaction Scale Ques-
tionnaire (CSQ-3) [85], respectively, over each scale’s mid-point; 2) 
more than 70% participants approached who agree to participate; 3) >
70% participate in at least 6 of 8 sessions; 4) more than 5 of 7 days of 
valid accelerometer data in >80% of participants; 5) > 4 of 7 days 
relaxation response practice, SMART goal, appreciation, behavioral 
activation OR > 5 of 7 days for one of the 3 components by > 70% of 
participants; 6) > 75% therapist adherence to sessions (checklist and 
audio recordings); 7) no questionnaires missing fully in >25% partici-
pants; 8) stable medications; 9) minimal adverse events (e.g., swelling, 
soreness, stiffness). 
The main purpose of Phases 2 and 3 are to determine the feasibility, 
acceptability, credibility and adherence of live video-delivered GetAc-
tive-OA. Neither trial is neither powered for efficacy nor aimed to pro-
vide such information. Consistent with the feasibility design of this trial, 
we will report means and standard deviations of all measures at all time 
points, including distribution of scores and internal consistency reli-
ability. To determine the measures’ sensitivity to detect change, we will 
report percent change in all quantitative outcomes within each group. 
We will also describe step count, types of activity (i.e., light, moderate 
and vigorous), and sedentary time measured by the accelerometers. 
Demographic and clinical variables will be summarized but efficacy 
analyses will not be conducted consistent with the R34 mechanism [88, 
89]. In addition, biomarkers of cartilage degradation (CTXII), bony 
remodeling (CTXIα), and systemic inflammation (IL-1β and TLR4) will 
be analyzed to determine if patient factors (e.g., age, biological sex, race, 
smoking status) influence biomarker concentrations to inform future 
analyses of covariate selection. Once these data analyses are completed, 
the multidisciplinary team will review the data and discuss the inter-
pretation of our findings in the context of current research on OA-related 
pain and physical function. 
3. Results 
We have completed enrollment for the Phase 1 focus groups with 
enrollment estimated to begin in March 2021 for the Phase 2 open pilot 
and July 2021 for the pilot RCT. The target date of completing the pilot 
RCT is November 2022. 
4. Discussion 
Regular physical activity has been reported to slow the progression 
of OA and reduce pain and limitations [90], whereas sedentary lifestyles 
and reduced mechanical loading result in thinning of the cartilage 
[91–93]. Barriers to engaging and adhering to physical exercise in those 
with chronic pain include coping difficulties (e.g., low self-efficacy, fear 
avoidance, catastrophic thinking about pain), programs that are too 
challenging (e.g., going to the gym, doing too much too soon), not 
meaningful, interfere with one’s life, or too difficult to implement 
[17–20]. Lack of physical activity and ineffective coping are common in 
individuals with obesity, depression and knee OA, and reinforce each 
other over time placing individuals on a disability spiral [45]. Depressed 
OA patients have a greater likelihood of reduced physical activity which 
may contribute to progressive cartilage degradation [5]. Depression, 
obesity, and knee OA are associated with sedentary behaviors and 
reduced physical activity [5], thereby creating a cycle of pain, inactivity, 
and cartilage degradation secondary to the systemic inflammatory 
burden for obese OA patients with depression. Walking is a safe physical 
activity in this population, preferred by participants, but challenging to 
adhere to and sustain over time. 
Mind-body programs are effective in decreasing depression, obesity, 
and pain in a variety of populations [94,95], including OA [96,97], but 
there are several current limitations. First, mind-body programs do not 
directly target increased walking necessary for proper loading of the 
knee joint, which may represent one reason why complementary and 
alternative medicine approaches have not successfully slowed OA pro-
gression [98]. Walking also has direct effects on depression and weight 
and has the potential to increase the efficacy of the mind-body skills. 
Second, conceptualization and assessment of physical function in 
mind-body clinical trials do not follow guidelines for both pain- 
(IMMPACT) [27,28] and OA-related clinical trials (OMERACT-OARSI) 
[99,100] and do not incorporate self-report measures of activity of daily 
living (biased due to perceptions but important to patients), 
performance-based measures (e.g., walk tests; still subject to bias due to 
motivation and perceptions), and more objective measures of physical 
function such as accelerometers (which are valid and comparable to live 
observations of activity). Third, programs do not address the comor-
bidity of depression, obesity, and OA which are direct barriers to 
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increased walking in this population. 
Our protocol was developed to directly address barriers to increased 
walking in this population, by adapting mind body skills to the unique 
needs of this population, and adding specific skills to help individuals set 
walking goals using quota based pacing. The proposed GetActive-OA 
will include SMART goal-setting in each session, evidenced-based 
skills previously found promising in chronic pain, OA, and depression 
when tested individually [101–104], embedded educational informa-
tion on healthy lifestyle (walking, diet, sleep), and a focus on adjusting 
to symptoms, rather than eliminate them. These skills combined with 
increased walking can target biological, psychological, and mechanical 
OA pathways. Multimodal programs such as GetActive-OA, that incor-
porate a variety of skills are more efficacious than unimodal programs 
[105]. Multimodal mind body programs are successfully delivered via 
live video [31]. GetActive-OA patients may represent a viable treatment 
option for individuals with comorbid depression, obesity and knee OA 
at-risk patient population. The GetActive-OA will accommodate a 6th 
grade reading level allowing for patients with low health literacy or 
learning disabilities to participate. 
The results of this mixed methods study will provide a realistic 
assessment of the study procedures as they will occur during the fully- 
powered efficacy trial, information on how participants might engage 
differently with the intervention and control, and signal of improvement 
in the intervention before investment of resources in the full RCT. These 
results will inform a fully powered RCT of GetActive-OA versus control 
to test efficacy and mechanisms of improvement through biological, 
psychological, and mechanical pathways. Our guiding hypotheses are 
that participation in the GetActive-OA will be associated with decreased 
pro-inflammatory IL-1β and TLR4 expression, increased resiliency skills, 
and an improved ability to engage and sustain participation in regular 
walking. In turn, these factors will be associated with decreased pain, 
depression and obesity, leading to better knee health and quality of life. 
4.1. Foreseen challenges 
Despite the innovative approach of this project, there are potential 
challenges. Based on patients available at the involved orthopedic cen-
ters, recruitment goals should be attainable, but we will consider 
expanding effort for in-person recruitment to additional primary care 
and orthopedic centers in the region if needed. We have also adapted our 
recruitment and screening processes as a result of the COVID-19 
response. Because the study procedures can be performed remotely 
without increasing risk to either the participant or research staff, the UK 
IRB has approved an study flyer that can electronically distributed at the 
participating institutions and circulated by patient advocacy groups 
such as the Arthritis Foundation. The informed consent process is 
completed with either electronic signatures or signed paper informed 
consent forms that can be either mailed or scanned and then emailed to 
the research staff. There may also be technological challenges for older 
knee OA patients when using live video. A research assistant will be 
available in real time to assist with any technological issues, consistent 
with our live video protocol for neurofibromatosis. If needed, we will 
offer accommodations for participants who need further assistance with 
the technology (e.g., set up on multiple devices, allowing participants to 
travel to a partnering clinic to participate in videoconferencing, offering 
webcams when not available, problem solving regarding travel to a 
family member’s or friend’s house to use other computers) as we have 
done in prior studies. Finally, patient retention could be potentially 
challenging. If group sizes fall below 3, we will consider adding in-
centives for adherence (e.g., giftcards for session adherence). We have 
not had this problem in any of our prior trials. 
4.2. Implications 
Approximately 1/3 of patients with knee OA experience a rapid 
progression of cartilage degradation, knee pain and disability [10] 
leading to a greater utilization of healthcare resources [106]. [-108] 
Patients with knee OA comorbid with both obesity and depression have 
significantly worse pain and subjective knee function, as well as 
significantly greater cartilage degradation than those without obesity or 
depression [6]. While it may seem that the subset of obese knee OA 
patients with comorbid depression is a very select subgroup, there is an 
impending “perfect storm” in terms of the prevalence of obese patients 
with comorbid depression that are predisposed to more rapid OA pro-
gression. The prevalence of obesity ranges between 37% and 40% for 
Americans above the age of 40 [109]. With the lifetime risk of devel-
oping symptomatic knee OA of 60% for obese individuals [110], it has 
been projected that more than 67 million Americans will suffer from OA 
by the year 2030 [111]. In addition, depression has been projected to be 
the most prevalent cause of disability by the year 2030 [112]. When one 
considers that approximately 20% of OA patients suffer from comorbid 
depression [113] and the increasing prevalence of obesity, knee OA, and 
depression, this seemingly narrow subset will soon include millions of 
Americans, making it a rising public health concern. 
To address this growing public health concern, Project DOORSTEP 
aims to adapt the GetActive for the needs of knee OA patients with 
depression and obesity with a focus on increasing walking, and itera-
tively establish the feasibility, credibility and acceptability of the pro-
grams and research procedures. The goals of adapting the GetActive for 
this population are to both reduce depressive symptoms and optimize 
mechanical loading of the articular cartilage. In doing so, the GetActive- 
OA may reduce knee symptoms, improve function and slow cartilage 
breakdown. There is an opportunity to greatly improve quality of life in 
this population, and delivery of the GetActive-OA program via secure 
telehealth bypasses many barriers to care, including absence of skilled 
providers in remote areas, missed work, and/or burden of travel (cost 
and reliance on family and friends). This is particularly relevant in our 
area of Kentucky where many of our rural patients lack access to care, 
and telehealth is their self-reported preferred treatment modality. 
By targeting modifiable influences of rapid OA progression and 
establishing a connection between comorbid obesity, depression, and 
the intraarticular knee environment, Project DOORSTEP will 1) provide 
for simple clinical methods to identify at-risk patients, and 2) trigger a 
line of innovative, multidisciplinary research to shift the treatment 
paradigm to move away from isolated treatment of the knee to a bio-
psychosocial model in which both the knee itself and the modifiable 
inflammatory conditions of obesity and depression are treated to 
potentially slow OA progression in the subset of patients at greatest risk. 
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